Clinical outcomes of uterine arterial chemoembolization with drug-eluting beads for advanced-stage or recurrent cervical cancer

2021 ◽  
Author(s):  
Yonghua Bi ◽  
Yanli Wang ◽  
Jianhao Zhang ◽  
Xiaonan Shi ◽  
Yang Wang ◽  
...  
Keyword(s):  
Cervical Cancer ◽  
Clinical Outcomes ◽  
Advanced Stage ◽  
Recurrent Cervical Cancer ◽  
Drug Eluting Beads ◽  
Drug Eluting ◽  
Arterial Chemoembolization

Safety and Effectiveness of Chemoembolization with Drug-Eluting Beads for Advanced-Stage Hepatocellular Carcinoma

2013 ◽  
Vol 37 (2) ◽  
pp. 381-387 ◽  
Author(s):  
Sanjeeva P. Kalva ◽  
Melina Pectasides ◽  
Raymond Liu ◽  
Niranjan Rachamreddy ◽  
Shravani Surakanti ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Advanced Stage ◽  
Drug Eluting Beads ◽  
Drug Eluting

Abstract No. 115: Follow-Up Imaging After Trans Arterial Chemoembolization with Drug Eluting Beads for Endocrine Tumors

2009 ◽  
Vol 20 (2) ◽  
pp. S45-S46
Author(s):  
L. Catherine ◽  
C. Teritheau ◽  
P. Rao ◽  
A. Hakime ◽  
F. Deschamps ◽  
...  
Keyword(s):  
Endocrine Tumors ◽  
Drug Eluting Beads ◽  
Drug Eluting ◽  
Arterial Chemoembolization

scholarly journals To Evaluate the Safety and Efficacy of Drug‐eluting Beads Bronchial Arterial Chemoembolization Loaded with Pirarubicin in the Treatment of Advanced Non-small-cell Lung Cancer

2021 ◽  
Author(s):  
Zhaonan Li ◽  
Quanjing Chen ◽  
Dechao Jiao ◽  
Xinwei Han
Keyword(s):  
Lung Cancer ◽  
Adverse Events ◽  
Small Cell Lung Cancer ◽  
Advanced Nsclc ◽  
Small Cell ◽  
Small Cell Lung ◽  
Drug Eluting Beads ◽  
Drug Eluting ◽  
Grade 3 ◽  
Arterial Chemoembolization

Abstract Objectives The control of solid tumors by drug-eluting beads has been recognized in clinical practice, but there are still few applications regarding drug‐eluting beads bronchial arterial chemoembolization (DEB‐BACE) in lung cancer. To further investigate the role of DEB-BACE in patients with lung cancer. We evaluated the efficacy and safety of Pirarubicin-loaded CalliSpheres beads in patients treated for advanced non-small cell lung cancer (NSCLC). MethodsFrom June 2017 to January 2018, 54 patients with advanced NSCLC received DEB‐BACE with Pirarubicin‐loaded CalliSpheres® beads. After the treatment, the progression-free survival (PFS) and overall survival (OS) were analyzed. Moreover, adverse events and complications were also reported. ResultsAfter DEB‐BACE treatment, most of the adverse events and complications were CTCAE grade 1 or 2 (mild symptoms, no or local/noninvasive intervention indicated) . Of the 54 patients, 2 persons (4%) had grade-3 lung abscess and required percutaneous drainage, 1(2%) had a grade-3 pulmonary infection that caused difficulty breathing and required intravenous antibiotics and ventilator adjuvant therapy. Moreover, the patient’s mean PFS was 7.828 months (95% CI: 6.614, 9.043), and the mean OS rates were 17.678 months (95% CI: 15.573, 19.783). Additionally, both univariate and multivariate cox regression indicated that the disease stage (stage III) seems related to better PFS in patients with advanced NSCLC (P=0.013). ConclusionsThe clinical effect of DEB‐BACE with Pirarubicin‐loaded CalliSpheres® beads on advanced NSCLC is probably significant and could improve the PFS, the adverse events and complications were tolerable.

Sign in / Sign up

Export Citation Format

Share Document